What is the present valuation and projected CAGR of the focal segmental glomerulosclerosis drugs market?
The focal segmental glomerulosclerosis drugs market size has grown strongly in recent years. It will grow from $15.77 billion in 2024 to $17.08 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing disease prevalence, growing demand for new treatments, growing interest from pharmaceutical sector, increasing government support.
The focal segmental glomerulosclerosis drugs market size is expected to see strong growth in the next few years. It will grow to $24.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to research and development expenditure, rising healthcare expenditure, growing awareness and diagnosis, aging population, government initiatives and funding. Major trends in the forecast period include technological advancements in drug discovery and development, expanding clinical trials pipeline, improved reimbursement for focal segmental glomerulosclerosis drugs treatments, expansion of corporate research facilities.
Get Your Free Sample of The Global Focal Segmental Glomerulosclerosis Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12866&type=smp
How has the focal segmental glomerulosclerosis drugs market evolved, and what factors have shaped its growth?
The rising prevalence of kidney infections is expected to propel the growth of the focal segmental glomerulosclerosis (FSGS) drugs market going forward. A kidney infection, or pyelonephritis, is a severe type of urinary tract infection (UTI) that affects one or both kidneys. Focal segmental glomerulosclerosis (FSGS) drugs, which are used to treat kidney diseases, offer several benefits in managing the condition and improving kidney function by reducing proteinuria, slowdowns the progression of kidney damage, and helping the patients suffering from kidney diseases with improved quality of life. For instance, in July 2022, according to the Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, around 15%, or 37 million people in the US, were affected by kidney disease. The prevalence among individuals aged 45–64 is 12% and the prevalence among people between 18 and 44 was 6% in 2021. Therefore, the rising prevalence of kidney infections drives the focal segmental glomerulosclerosis (FSGS) market.
What are the major segments of the focal segmental glomerulosclerosis drugs market?
The focal segmental glomerulosclerosis drugs market covered in this report is segmented –
1) By Type: Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types
2) By Treatment: Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments
3) By Route of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-drugs-global-market-report
Which companies dominate the focal segmental glomerulosclerosis drugs market?
Major companies operating in the focal segmental glomerulosclerosis drugs market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Fresenius Kabi Ltd., GSK PLC, Medtronic Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Alexion Pharmaceuticals, Wockhardt, Travere Therapeutics, Aurinia Pharmaceuticals Inc., Omeros Corporation, Dimerix Ltd., Goldfinch Bio.
How will evolving trends contribute to the growth of the focal segmental glomerulosclerosis drugs market?
Major companies operating in the focal segmental glomerulosclerosis (FSGS) market are increasingly focusing on product development and innovation to provide reliable products to their customers and strengthen their market position. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, launched FILSPARI, for focal segmental glomerulosclerosis (FSGS), which was approved by the Food and Drug Administration (FDA), a US-based federal agency. It is an oral medicine for treating IgA nephropathy (IgAN). It is the first and only non-immunosuppressive treatment for lowering proteinuria in IgAN, a rare kidney disease. Additionally, FILSPARI has been given orphan drug designation in the United States and Europe for treating IgAN and focal segmental glomerulosclerosis (FSGS).
What are the key regional dynamics of the focal segmental glomerulosclerosis drugs market, and which region leads in market share?
North America was the largest region in the focal segmental glomerulosclerosis drugs market in 2024. The regions covered in the focal segmental glomerulosclerosis (FSGS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Focal Segmental Glomerulosclerosis Drugs Market Report 2025 Offer?
The focal segmental glomerulosclerosis drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Focal segmental glomerulosclerosis (FSGS) is a rare type of kidney disease that causes scarring in the kidneys’ filters. Focal segmental glomerulosclerosis (FSGS) drugs refer to medications used to treat and manage the progression of the disease.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12866
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
